Passage Bio Inc. (PASG) NASDAQ

$1.14 (0.01) (-0.87%)

Market Cap: $70.85M

As of 04/22/24 04:00 PM EDT. Market closed.

(PASG)

Passage Bio Inc. (PASG)
NASDAQ

$1.14
(0.01) (-0.87%)

Market Cap: $70.85M

As of 04/22/24 04:00 PM EDT. Market closed.

Add to Portfolio

passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã?-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to ... read more

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
111
Address
.
PRICE CHART FOR PASSAGE BIO INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$1.15
Previous Close
$1.15
Days Range
$1.13 - $1.20
52 week range
$0.58 - $1.79
Volume
84,360
Avg. Volume (30 days)
167,235
Market Cap
$70.85M
Dividend Yield
-
P/E
-
Shares Outstanding
61,611,796
Open
$1.15
Previous Close
$1.15
Days Range
$1.13 - $1.20
52 week range
$0.58 - $1.79
Volume
84,360
Avg. Volume (30 days)
167,235
Market Cap
$70.85M
Dividend Yield
-
P/E
-
Shares Outstanding
61,611,796
FINANCIAL STATEMENTS FOR PASSAGE BIO INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR PASSAGE BIO INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Borthwick KathleenSVP, INTERIM CFOFeb 13, 2024 Sale$0.971,4701,42628,466Feb 13, 2024, 07:36 PM
Forman Mark SCHIEF MEDICAL OFFICERFeb 13, 2024 Sale$0.971,6381,58948,631Feb 13, 2024, 07:34 PM
King SimonaChief Financial OfficerJul 28, 2023 Sale$0.8811,45310,07923,994Aug 01, 2023, 04:36 PM
ORBIMED ADVISORS LLC10% OwnerJun 28, 2023 Buy$0.84575,195483,1648,034,000Jun 29, 2023, 04:42 PM
ORBIMED ADVISORS LLC10% OwnerJun 27, 2023 Buy$0.84617,382518,6017,458,805Jun 29, 2023, 04:42 PM
Fotopoulos AlexandrosChief Technical OfficerJun 16, 2023 Sale$0.934,0523,77828,693Jun 20, 2023, 04:10 PM
King SimonaChief Financial OfficerApr 18, 2023 Sale$1.052,0532,1562,053Apr 20, 2023, 04:28 PM
Kapadia SandipDirectorDec 01, 2022 Sale$1.195,0005,9640Dec 02, 2022, 05:14 PM
Fotopoulos AlexandrosChief Technical OfficerNov 22, 2022 Sale$1.333,7204,94820,245Nov 25, 2022, 04:15 PM
Toernsen Monika MariaChief Commercial OfficerSep 19, 2022 Sale$1.511,6812,5393,319Nov 18, 2022, 05:01 PM
ORBIMED ADVISORS LLC10% OwnerMay 03, 2022 Buy$1.93221,500427,4956,537,923May 05, 2022, 05:23 PM
ORBIMED ADVISORS LLC10% OwnerMay 04, 2022 Buy$1.94303,500588,7906,841,423May 05, 2022, 05:23 PM
ORBIMED ADVISORS LLC10% OwnerJan 20, 2022 Buy$5.0050,800254,0006,316,423May 05, 2022, 05:11 PM
Goldsmith Bruce ACEO and PresidentMar 21, 2022 Buy$3.1510,00031,50015,983Mar 23, 2022, 04:43 PM
ORBIMED ADVISORS LLC10% OwnerJan 20, 2022 Buy$5.42369,1002,000,5226,634,723Jan 24, 2022, 04:44 PM
ORBIMED ADVISORS LLC10% OwnerJan 14, 2022 Buy$5.6010,30057,6806,107,623Jan 20, 2022, 06:03 PM
ORBIMED ADVISORS LLC10% OwnerJan 19, 2022 Buy$5.1143,300221,2636,265,623Jan 20, 2022, 06:03 PM
ORBIMED ADVISORS LLC10% OwnerJan 18, 2022 Buy$5.46114,700626,2626,222,323Jan 20, 2022, 06:03 PM
ORBIMED ADVISORS LLC10% OwnerJan 13, 2022 Buy$5.5241,800230,7366,097,323Jan 13, 2022, 07:37 PM
ORBIMED ADVISORS LLC10% OwnerJan 12, 2022 Buy$5.65100,000565,0006,055,523Jan 13, 2022, 07:37 PM
ORBIMED ADVISORS LLC10% OwnerJan 11, 2022 Buy$5.538,20045,3465,955,523Jan 13, 2022, 07:37 PM
Quigley Jill M.Chief Operating OfficerDec 08, 2021 Option Exercise$0.2371,97516,554368,754Dec 10, 2021, 05:30 PM
Romano GaryChief Medical OfficerMar 15, 2021 Option Exercise$8.0710,00080,70010,000Mar 17, 2021, 09:12 PM
Romano GaryChief Medical OfficerMar 15, 2021 Sale$21.1010,000211,0131,617Mar 17, 2021, 09:12 PM
Quigley Jill M.Chief Operating OfficerJan 20, 2021 Sale$30.011,30039,011295,284Jan 22, 2021, 05:54 PM
Quigley Jill M.Chief Operating OfficerJan 14, 2021 Sale$30.1016,298490,570296,584Jan 15, 2021, 08:29 PM
Countouriotis AthenaDirectorMar 24, 2020 Buy$14.9810,000149,75018,900Mar 25, 2020, 08:26 PM
Ratcliffe LiamDirectorMar 03, 2020 Buy$18.002,80050,4002,800Mar 13, 2020, 05:20 PM
Ratcliffe LiamDirectorMar 03, 2020 Buy$18.00550,0009,900,0002,616,630Mar 13, 2020, 05:20 PM
ORBIMED ADVISORS LLC10% OwnerFeb 28, 2020 Buy$18.00373,3006,719,400373,300Mar 03, 2020, 07:07 PM
Versant Venture Capital VI, L.P.10% OwnerMar 03, 2020 Buy$18.00225,0004,050,000933,352Mar 03, 2020, 07:03 PM
Frazier Life Sciences IX, L.P.10% OwnerMar 03, 2020 Buy$18.00550,0009,900,0005,009,219Mar 03, 2020, 06:59 PM
Woiwode ThomasDirectorMar 03, 2020 Buy$18.00225,0004,050,000933,352Mar 03, 2020, 06:57 PM
Heron Patrick JDirectorMar 03, 2020 Buy$18.00550,0009,900,0005,009,219Mar 03, 2020, 06:54 PM
Yamada TadatakaDirectorMar 03, 2020 Buy$18.006,500117,000656,149Mar 03, 2020, 06:51 PM
Ratcliffe LiamDirectorMar 03, 2020 Buy$18.002,80050,4002,800Mar 03, 2020, 06:48 PM
Quigley Jill M.Chief Operating OfficerMar 03, 2020 Buy$18.001,00018,0001,000Mar 03, 2020, 06:46 PM
Quigley Jill M.Chief Operating OfficerMar 03, 2020 Buy$18.001,50027,000311,494Mar 03, 2020, 06:46 PM
Morris Richard StevenChief Financial OfficerMar 03, 2020 Buy$18.004007,200400Mar 03, 2020, 06:44 PM
Kapadia SandipDirectorMar 03, 2020 Buy$18.005,00090,0005,000Mar 03, 2020, 06:43 PM
Islam SaqibDirectorMar 03, 2020 Buy$18.005,00090,0005,000Mar 03, 2020, 06:41 PM
Goldsmith Bruce ACEO and PresidentMar 03, 2020 Buy$18.001,10019,8001,100Mar 03, 2020, 06:40 PM
Fotopoulos AlexandrosChief Technical OfficerMar 03, 2020 Buy$18.005,50099,0005,500Mar 03, 2020, 06:38 PM
Countouriotis AthenaDirectorMar 03, 2020 Buy$18.008,900160,2008,900Mar 03, 2020, 06:37 PM
Cale Edgar B.GC and Corporate SecretaryMar 03, 2020 Buy$18.002,00036,0002,000Mar 03, 2020, 06:35 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Borthwick KathleenSVP, INTERIM CFO02/13/20241,426
Forman Mark SCHIEF MEDICAL OFFICER02/13/20241,589
King SimonaChief Financial Officer07/28/202310,079
ORBIMED ADVISORS LLC10% Owner06/28/2023483,164
ORBIMED ADVISORS LLC10% Owner06/27/2023518,601
Fotopoulos AlexandrosChief Technical Officer06/16/20233,778
King SimonaChief Financial Officer04/18/20232,156
Kapadia SandipDirector12/01/20225,964
Fotopoulos AlexandrosChief Technical Officer11/22/20224,948
Toernsen Monika MariaChief Commercial Officer09/19/20222,539
ORBIMED ADVISORS LLC10% Owner05/03/2022427,495
ORBIMED ADVISORS LLC10% Owner05/04/2022588,790
ORBIMED ADVISORS LLC10% Owner01/20/2022254,000
Goldsmith Bruce ACEO and President03/21/202231,500
ORBIMED ADVISORS LLC10% Owner01/20/20222,000,522
ORBIMED ADVISORS LLC10% Owner01/14/202257,680
ORBIMED ADVISORS LLC10% Owner01/19/2022221,263
ORBIMED ADVISORS LLC10% Owner01/18/2022626,262
ORBIMED ADVISORS LLC10% Owner01/13/2022230,736
ORBIMED ADVISORS LLC10% Owner01/12/2022565,000
ORBIMED ADVISORS LLC10% Owner01/11/202245,346
Quigley Jill M.Chief Operating Officer12/08/202116,554
Romano GaryChief Medical Officer03/15/202180,700
Romano GaryChief Medical Officer03/15/2021211,013
Quigley Jill M.Chief Operating Officer01/20/202139,011
Quigley Jill M.Chief Operating Officer01/14/2021490,570
Countouriotis AthenaDirector03/24/2020149,750
Ratcliffe LiamDirector03/03/202050,400
Ratcliffe LiamDirector03/03/20209,900,000
ORBIMED ADVISORS LLC10% Owner02/28/20206,719,400
Versant Venture Capital VI, L.P.10% Owner03/03/20204,050,000
Frazier Life Sciences IX, L.P.10% Owner03/03/20209,900,000
Woiwode ThomasDirector03/03/20204,050,000
Heron Patrick JDirector03/03/20209,900,000
Yamada TadatakaDirector03/03/2020117,000
Ratcliffe LiamDirector03/03/202050,400
Quigley Jill M.Chief Operating Officer03/03/202018,000
Quigley Jill M.Chief Operating Officer03/03/202027,000
Morris Richard StevenChief Financial Officer03/03/20207,200
Kapadia SandipDirector03/03/202090,000
Islam SaqibDirector03/03/202090,000
Goldsmith Bruce ACEO and President03/03/202019,800
Fotopoulos AlexandrosChief Technical Officer03/03/202099,000
Countouriotis AthenaDirector03/03/2020160,200
Cale Edgar B.GC and Corporate Secretary03/03/202036,000
Load More Insider Transactions
FUNDS WITH A POSITION IN PASSAGE BIO INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
ORBIMED ADVISORS LLC8,034,0000.21%-20.65%Other
RENAISSANCE TECHNOLOGIES LLC1,223,3510.00191%23.02%Other
BLACKROCK INC.1,022,5630.00003%1.01%Other
GEODE CAPITAL MANAGEMENT, LLC332,2030.00004%No changeOther
CHANGE IN SHARES OUTSTANDING FOR PASSAGE BIO INC
STOCK BUYBACKS FOR PASSAGE BIO INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
0.17%
1Q
12/31/2023
06/30/2023
0.36%
2Q
12/31/2023
03/31/2023
0.48%
3Q
12/31/2023
12/31/2022
0.55%
4Q
12/31/2023
09/30/2022
0.75%
5Q
12/31/2023
06/30/2022
0.91%
6Q
12/31/2023
03/31/2022
1.11%
7Q
12/31/2023
12/31/2021
1.38%
8Q
12/31/2023
09/30/2021
1.64%
9Q
12/31/2023
06/30/2021
1.85%
10Q
12/31/2023
03/31/2021
6.91%
11Q
12/31/2023
12/31/2020
20.24%
12Q
12/31/2023
09/30/2020
20.61%
13Q
12/31/2023
06/30/2020
20.92%
14Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
0.17%
1Q
06/30/2023
0.36%
2Q
03/31/2023
0.48%
3Q
12/31/2022
0.55%
4Q
09/30/2022
0.75%
5Q
06/30/2022
0.91%
6Q
03/31/2022
1.11%
7Q
12/31/2021
1.38%
8Q
09/30/2021
1.64%
9Q
06/30/2021
1.85%
10Q
03/31/2021
6.91%
11Q
12/31/2020
20.24%
12Q
09/30/2020
20.61%
13Q
06/30/2020
20.92%
14Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR PASSAGE BIO INC
LOADING...